Beta-turn Peptidomimetic Cyclic Compounds for Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye, such as artificial tears and anti-inflammatory medications, have limited long-term efficacy and are associated with side effects like ocular pain and poor pharmacokinetics, necessitating the development of alternative methods for improving tear film stability and ocular surface health.
Innovation Solution
Administration of a β-turn peptidomimetic cyclic compound, specifically a macrocyclic ring structure with defined substituents and linking groups, which acts as a Trk modulator to stimulate mucin secretion and enhance tear film stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If anti-inflammatory medication is administered to treat dry eye, then tear production is increased, but ocular pain occurs as a side effect
Solution Approach 1:
The patent uses peptide compounds as intermediary substances that bind to nerve growth factor receptors to modulate neural signaling. These peptide intermediaries activate trophic pathways that stimulate tear production through indirect neural regulation rather than direct anti-inflammatory action, thereby avoiding the ocular pain side effect associated with conventional anti-inflammatory medications while achieving the desired increase in tear secretion
2Quantity of substance
If punctual tamponade occlusion is performed to improve aqueous tear film content, then tear retention is enhanced, but tear production and clearance are reduced
Solution Approach 1:
The patent employs peptide compounds that activate endogenous neural pathways to stimulate the lacrimal glands to produce tears autonomously. This self-service mechanism restores the body's natural tear production capability through trophic signaling, eliminating the need for mechanical occlusion devices that would otherwise be required to retain tears, thereby maintaining both tear production and clearance functions
3Quantity of substance
If RESTASIS (cyclosporine A) is administered to increase tear production, then tear secretion is improved, but long-term control therapy utility is limited
Solution Approach 1:
The patent utilizes peptide compounds with modified molecular structures that exhibit improved pharmacokinetic properties compared to cyclosporine A. These peptide parameters include enhanced stability, bioavailability, and receptor binding characteristics, which enable sustained activation of trophic pathways over long periods. The altered molecular parameters allow for prolonged therapeutic effect and reduced dosing frequency, providing superior long-term control therapy for dry eye disease
Data Source
AI summary
The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye.